Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Treasury Shares (2022 - 2024)

Historic Treasury Shares for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q4 2024 value amounting to $2.1 million.

  • Zentalis Pharmaceuticals' Treasury Shares rose 7017.46% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 7017.46%. This contributed to the annual value of $2.1 million for FY2024, which is 7017.46% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Treasury Shares stood at $2.1 million for Q4 2024, which was up 7017.46% from $1.2 million recorded in Q4 2023.
  • Over the past 5 years, Zentalis Pharmaceuticals' Treasury Shares peaked at $2.1 million during Q4 2024, and registered a low of $922901.0 during Q4 2022.
  • Over the past 3 years, Zentalis Pharmaceuticals' median Treasury Shares value was $1.2 million (recorded in 2023), while the average stood at $1.4 million.
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Treasury Shares skyrocketed by 3206.35% in 2023 and then skyrocketed by 7017.46% in 2024.
  • Over the past 3 years, Zentalis Pharmaceuticals' Treasury Shares (Quarter) stood at $922901.0 in 2022, then skyrocketed by 32.06% to $1.2 million in 2023, then skyrocketed by 70.17% to $2.1 million in 2024.
  • Its Treasury Shares stands at $2.1 million for Q4 2024, versus $1.2 million for Q4 2023 and $922901.0 for Q4 2022.